1 / 24

13 th December 2006

Stem Cells Hope or Hype?. Paul Rodgers. 13 th December 2006. Ithaka Life Sciences Ltd. Business started in 2000 Commercialising life science technologies: Business creation Technical, commercial and market evaluation Intellectual property review

chen
Télécharger la présentation

13 th December 2006

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Stem Cells Hope or Hype? Paul Rodgers 13th December 2006

  2. Ithaka Life Sciences Ltd • Business started in 2000 • Commercialising life science technologies: • Business creation • Technical, commercial and market evaluation • Intellectual property review • Business plans: due diligence and drafting • Business development, M&A, licensing, disposal • Sourcing investment finance • Interim management

  3. Ithaka Life Sciences Ltd • Stem Cells • Axordia Ltd • CereStem Ltd • British Stem Cell Registry Ltd • Centre of Excellence for Life Sciences Ltd • Plasticell Ltd • bioProcess UK • Cardiff University • Manchester University

  4. Overview • What’s the problem? • Hype? • Reality? • Hope? • Conclusions

  5. What’s the problem?

  6. Unmet Medical Need • Diabetes • 12.1 million sufferers in US (2002) • Costs $132 billion p.a. (2002) rising to $156 billion p.a. (2010) • Cardiovascular disease • 64.4 million cases in US (2004) • Costs $368.4 billion p.a. (2004) • Parkinson’s Disease • 100,000 sufferers in UK • Treatment costs £600 million p.a. (1998)

  7. Degenerative Diseases • Other examples • Alzheimer’s, spinal cord injuries, Amyotrophic Lateral Sclerosis, multiple sclerosis, liver diseaseetc • Restoration of cell or organ function • Current drugs don’t treat the cause • Organ transplants • Expensive, donor shortages, not applicable to many diseases

  8. Hype

  9. Embryonic Stem Cells • Immortal • A single cell line is all you need • Precursors of all cell types • Can produce any cell you need • Can divide without limit • Unlimited supply

  10. Adult Stem Cells • Can be isolated from most tissues • e.g. bone marrow, cord blood, fat, skin etc • Generate cell types of tissue of origin • Produce useful cells for therapies • Plasticity • Can be coaxed into forming cells of completely different tissues • e.g. neurons from blood cells

  11. Reality

  12. Embryonic Stem Cells: Issues (1) • Derivation • Ethics and logistics (is SNCT a solution?) • Manufacture • Feeder cells; TSE; genetic stability; GMP • Safety • Uncontrolled cell proliferation; reprogramming; immune rejection • Differentiation • Reproducible production of desired cell type with appropriate functionality (typical yield <10%)

  13. Embryonic Stem Cells: Issues (2) • Efficacy • Dose, delivery and functionality • Economics • Uncertain regulatory requirements • Freedom to operate

  14. Embryonic Stem Cells Survey • ES cell therapy is 10-15 years away • Will be used to treat certain diseases • Diabetes, cardiovascular, single gene defects, MS, Alzheimer’s, Parkinson’s, liver disease, spinal cord injury, retinal disease • Schering and Merck are the only pharma companies to say they are interested at this stage

  15. Adult Stem Cells: Issues • Derivation • Tissues other than bone marrow and cord blood? • Differentiation • Reproducible production of cells of completely different tissues • Therapeutic benefit • Implanted cells often die due to immune attack • Unexpected side effects (e.g. foetal neurons in Parkinsons) • Economics of autologous cell therapy

  16. Hope

  17. Islet Cell Therapy • Edmonton protocol (1999) • Cells injected into liver via hepatic portal vein under local anaesthetic • >300 patients: 84% success rate reported (insulin-free) • But • Immunosuppressive drugs required • Requires 2-4 pancreata per patient • Only 1,100 pancreata available for 1.1 million Type 1 diabetes sufferers in US • Side effects and decline in performance with time

  18. Islet Cell Therapy

  19. Clinical Use of Adult Stem Cells • Bone marrow transplants • Replace blood cells ablated by cancer therapies • ~ 300 clinical studies on haematopoietic stem cells • Cell expansion is a key issue • Haematopoietic stem cells may be able to restore function to damaged cardiac tissue (3 trials so far) • Neural stem cell trial started in 2006 • Batten’s disease (Stem Cells Inc.) • Developments in China and Korea

  20. Brain Repair: Neural Stem Cells

  21. Progress with ES Cells • Manufacture • Feeder cell-free culture of human ES cells • Efficacy • Cardiomyocytes derived from human ES cells can restore some myocardial function in a pig model of cardiac disease • Clinical studies may start in 2007 • Congenital heart failure (ES Cell), spinal cord injury (Geron) or diabetes (Geron)

  22. But……….. • All the key issues remain to be addressed • How will clinical grade cells be produced economically and used effectively? • Regulatory uncertainty • Registration requirements • Ethical issues (especially in USA)

  23. Conclusion • We still have mountains to climb • Alps for adult stem cells • Himalayas for embryonic stem cells

  24. Information Sources http://stemcells.nih.gov/info/basics/ www.stemcellresearchnews.com/ www.aastrom.com www.neuronova.com www.athersys.com www.novocell.com www.cellartis.com www.stemcellsinc.com www.escellinternational.com www.gamida-cell.com www.geron.com www.stemcellsciencesltd.com Nature Biotechnology July 2005 issue

More Related